Following a forecast 0.3% decline in GDP in Q3, the UK economy is expected to contract around 0.2% each quarter from Q4 this year through to Q2 2023, resulting in GDP falling 0.3% in 2023 as a whole. This is a significant revision from the 1% growth forecast for 2023 in the EY ITEM Club’s July Summer Forecast – although the scale of the upcoming downturn is expected to be shallow relative to previous recessions thanks, in part, to the Government’s intervention on household and business energy bills. As the squeeze on real incomes from high inflation eases, tax cuts take effect, the cheap…

The US and European medical technology (MedTech) industry has performed impressively throughout the COVID-19 pandemic, but it now faces a host of new and emerging challenges as the direct impact of the global pandemic slowly subsides. As the 16th annual edition of our Pulse of the industry medical technology report shows, the industry’s revenues passed the notable milestone of a half-trillion dollars for the first time ever in 2021, driven by the resumption of deferred elective procedures and ongoing sales of pandemic-related products (particularly diagnostics and research-related laboratory…

We are excited to announce that as part of our investment programme we have introduced a high-end, ultra-fast and super-efficient slide digitalization system into our workflow. The PANNORAMIC® 1000 RX, is the flagship member of the 3DHISTECH PANNORAMIC® scanner family. It is known for its unprecedented capacity, superior image quality and flexibility. A range of scanning options are available, with brightfield scanning at resolutions of 20x, 40x, with Z stack and extended focus scanning options available too. Where extra detailed resolution is required, as of today, we are the only laboratory…

The EY Global IPO Trends 2022 is now available showing that after a record-breaking 2021, the global IPO market took a sharp turn in the opposite direction in 2022. With only 1,333 IPOs raising US$179.5b, IPO activity dipped 45% and 61% by number of deals and proceeds, respectively, year-over-year (YOY). As the average deal size shrank due to lowered valuation and poor stock market performance, we didn’t see as many large IPOs launch in 2022. Click here to view the full articles - https://www.ey.com/en_gl/ipo/trends

Despite a downturn in dealmaking, as companies seek to secure growth through innovation, M&A will need to take a central strategic role. In brief: - 2022 was a slow year for dealmaking in the life sciences but the final quarter saw a major uptick. - Conditions are right for major M&A with record firepower and a wealth of targets for 2023. - Companies will focus on the right strategic deals, which will include access to data and new technologies to secure future growth. - Click here to view the full report - https://go.ey.com/3CCUYm7

Riverlabs has got what everyone wants… • A 28-acre life science campus which will deliver 440,000 sq ft of lab space across three phases with 141,423 sq ft (GIA) of ready-built, affordable, wet laboratory and write-up space available NOW. • Situated in Ware, Hertfordshire, within a 45 min radius of London, Cambridge and the established Cell & Gene Therapy cluster in Stevenage, putting occupiers at the heart of the Golden Triangle. • An unrivalled opportunity for fast growing life sciences companies and ambitious, scaling contract research/manufacturing organisations wanting direct and…

AMSBIO is a leading supplier of cryopreserved primary human cells for research from multiple organs including the lung, liver, intestine, and kidney. Drawing upon well-established partnerships with respected organ procurement organizations, AMSBIO has access to samples that allow direct isolation of a wide range of cells that retain their original morphological and functional characteristics. Every batch of cells is validated for cell viability, morphology, plating efficiency and cell marker data. Cells are cultured for 5-7 days before being released and delivered with donor demographics…

• Ready built, affordable, wet laboratory and write-up space situated in Ware - an established life science location between London and Cambridge. • Riverlabs 1: 113,297 sq ft (GIA) available for fit out from January 2023. • Riverlabs 2: 219,900 sq ft (GIA) available for fit out in May 2023. • Situated on the River Lea with direct river access, Riverlabs enjoys unparalleled amenity providing the perfect environment for life science companies to thrive. London, UK, Tuesday 15th November 2022: European and US real estate asset manager and investor, Global Mutual, founded in 2008, today confirms…

View the latest updates on One Nucleus careers conferece, Building Life Science Adventures 2023. Join us for the annual Building Life Science Adventures (BLSA) careers conference on 28-29 March 2023. Creating careers, not just jobs, is a two-way process between those seeking to build their adventures in science and those seeking to build the best teams. This One Nucleus careers conference is free to attend and a chance to fill knowledge gaps, debate best practice and connect to enable success. Sign up now!

• New logo and website created to reflect Leaf’s progression • Better user experience with in-depth information on services and R&D Norwich, UK - 24 January 2023 Leaf Expression Systems (Leaf), a plant-based contract research and product development company working to serve the global life sciences (human and animal health), agribiotech, food and consumer care industries has launched a new logo and website, leafexpressionsystems.com. The logo and website reflect the progression Leaf has made from an academic spin-out to an established commercial organisation with a clear mission - to use…